About Us

AGEPHA Pharma is a family-owned and operated, leading multinational pharmaceutical company focused on bringing treatments to patients who need them most.

About Us

AGEPHA Pharma is a family-owned and operated, leading multinational pharmaceutical company focused on bringing treatments to patients who need them most.

Improving lives for over 70 years

1947

Founded in Vienna, Austria

AGEPHA Pharma traces its roots back to its founded in Vienna, Austria, where a commitment to advancing healthcare and improving lives became the cornerstone of our enduring mission.

2009

Purchase of Ophthalmic Product from Novartis

A strategic milestone was achieved with the acquisition of two ophthalmic products from Novartis, expanding our capabilities to provide cutting-edge solutions for eye care and reinforcing our dedication to comprehensive health.

2019

Introduced Xorox to 24 new countries

Market authorization for Xorox (Aciclovir Agepha) has been issued to 24 countries including Australia, Switzerland, UK, Ireland

2020

Launch of 50th Product

Celebrating a significant achievement, AGEPHA Pharma proudly marked the launch of its 50th product, a testament to our ongoing commitment to innovation and the diverse range of healthcare solutions we bring to patients around the world.

2023

US FDA Approval of LODOCO (Colchicine) Tablets

A pivotal moment in our journey unfolded with the FDA approval of LODOCO (colchicine) tablets, exemplifying our dedication to meeting critical healthcare needs and delivering effective treatments for improved patient outcomes.
Know more

Improving lives for over 70 years

1947

Founded in Vienna, Austria

AGEPHA Pharma traces its roots back to its founding in Vienna, Austria, where a commitment to advancing healthcare and improving lives became the cornerstone of our enduring mission.

2009

Purchase of Ophthalmic Product from Novartis

A strategic milestone was achieved with the acquisition of the ophthalmic product from Novartis, expanding our capabilities to provide cutting-edge solutions for eye care and reinforcing our dedication to comprehensive health.

2019

Introduced Xorox to 24 new countries

Market authorization for Xorox (Aciclovir Agepha) has been issued to 24 countries including (including Australia, Switzerland, UK, Ireland)

2020

Launch of 50th Product

Celebrating a significant achievement, AGEPHA Pharma proudly marked the launch of its 50th product, a testament to our ongoing commitment to innovation and the diverse range of healthcare solutions we bring to patients around the world.

2023

US FDA Approval of LODOCO (Colchicine) Tablets

A pivotal moment in our journey unfolded with the FDA approval of LODOCO (colchicine) tablets, exemplifying our dedication to meeting critical healthcare needs and delivering effective treatments for improved patient outcomes.
Contact Us

We’re Committed

Putting Patients First

Patients are at the heart of everything we do. We never lose sight of our goal to provide all patients with access to needed medications through self-funded endeavors. We work tirelessly with clinicians to understand unmet needs, and discover new ways to meet them.

Putting Patients First

Patients are at the heart of everything we do. We never lose sight of our goal to provide all patients with access to needed medications through self-funded endeavors. We work tirelessly with clinicians to understand unmet needs, and discover new ways to meet them.

Steve Andrzejewski

Co-Chair of the Board

Bio